News

George O. Waring IV, MD, FACS, discusses the “vision for a lifetime” approach and how modern advancements allow tailored treatments for every stage of eye maturity.

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.

Majmudar encourages young surgeons to seek hands-on experience early and often, stressing the importance of real-world practice beyond the classroom.

Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.

Explore innovative glaucoma treatments and technologies, including AI, home monitoring, and new surgical options, to enhance patient care.

Discover groundbreaking advancements in eye care at ASCRS 2025, featuring innovative technologies and research from leading ophthalmology companies.

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions.

Paediatric diagnoses of juvenile idiopathic intracranial hypertension, optic neuritis and Horner syndrome

From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption

Novel color created, olo, beyond previous human perception.

ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.

Bausch + Lomb addresses recent IOL recall, ensuring safety with enhanced protocols and returning enVista lenses to market after thorough investigation.

Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.

This population requires careful attention from diagnosis through the entire postoperative process.

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis

Abby Markward, MBA, executive director of the ASCRS Foundation and the ASOA, provides a sneak peek of the posterior segment-focused event.

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

Marsh will begin her role as COO April 28.

A five-step approach to personalise and simplify treatment, leading to higher efficacy

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.